

# Beom Soo Shin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5605225/publications.pdf>

Version: 2024-02-01

130  
papers

3,472  
citations

101543

36  
h-index

168389

53  
g-index

133  
all docs

133  
docs citations

133  
times ranked

5692  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0143621.	3.2	9
2	Comparison of the exposure assessment of di(2-ethylhexyl) phthalate between the PBPK model-based reverse dosimetry and scenario-based analysis: A Korean general population study. <i>Chemosphere</i> , 2022, 294, 133549.	8.2	1
3	Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions. <i>Journal of Controlled Release</i> , 2022, 343, 443-456.	9.9	4
4	Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis. <i>Molecules</i> , 2022, 27, 1881.	3.8	4
5	Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study. <i>Pharmaceutics</i> , 2022, 14, 1226.	4.5	0
6	Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1000-1020.	4.7	10
7	Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells. <i>Anticancer Research</i> , 2021, 41, 757-764.	1.1	0
8	Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity. <i>Advanced Therapeutics</i> , 2021, 4, 2000208.	3.2	6
9	Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. <i>Pharmaceutics</i> , 2020, 12, 824.	4.5	4
10	3D-Printed Gastroretentive Sustained Release Drug Delivery System by Applying Design of Experiment Approach. <i>Molecules</i> , 2020, 25, 2330.	3.8	17
11	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five $\beta$ -Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> . <i>MBio</i> , 2020, 11, .	4.1	17
12	Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study. <i>AAPS Journal</i> , 2020, 22, 27.	4.4	10
13	Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 143-156.	3.5	15
14	Comprehensive Study of Intermediate and Critical Quality Attributes for Process Control of High-Shear Wet Granulation Using Multivariate Analysis and the Quality by Design Approach. <i>Pharmaceutics</i> , 2019, 11, 252.	4.5	21
15	Liquid Chromatography-Tandem Mass Spectrometry of Desoxo-Narchinol a and Its Pharmacokinetics and Oral Bioavailability in Rats and Mice. <i>Molecules</i> , 2019, 24, 2037.	3.8	3
16	Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution. <i>Pharmaceutics</i> , 2019, 11, 251.	4.5	23
17	Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs. <i>PLoS ONE</i> , 2019, 14, e0216875.	2.5	63
18	Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. <i>Pharmaceutics</i> , 2019, 11, 133.	4.5	15

#	ARTICLE	IF	CITATIONS
19	Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats. <i>Marine Drugs</i> , 2019, 17, 171.	4.6	4
20	Small gold nanorods-loaded hybrid albumin nanoparticles with high photothermal efficacy for tumor ablation. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 179, 340-351.	5.0	30
21	Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative. <i>Anticancer Research</i> , 2019, 39, 759-769.	1.1	3
22	Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. <i>International Journal of Pharmaceutics</i> , 2019, 556, 276-286.	5.2	13
23	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 65-71.	2.5	1
24	Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1047-1052.	3.3	7
25	Simultaneous analysis of acetylcarnitine, proline, hydroxyproline, citrulline, and arginine as potential plasma biomarkers to evaluate NSAIDs-induced gastric injury by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 101-111.	2.8	17
26	Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells. <i>Journal of Radiation Protection and Research</i> , 2019, 44, 15-25.	0.6	1
27	Tissue distribution of gold and silver after subacute intravenous injection of co-administered gold and silver nanoparticles of similar sizes. <i>Archives of Toxicology</i> , 2018, 92, 1393-1405.	4.2	25
28	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable <i>Pseudomonas aeruginosa</i> via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	31
29	Combating Carbapenem-Resistant <i>Acinetobacter baumannii</i> by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
30	Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats. <i>Chinese Journal of Integrative Medicine</i> , 2018, 24, 460-466.	1.6	2
31	Model-based drug development: application of modeling and simulation in drug development. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 431-441.	5.3	33
32	HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 150, 39-42.	2.8	7
33	Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats. <i>Pharmaceutics</i> , 2018, 10, 174.	4.5	5
34	Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats. <i>Pharmaceutics</i> , 2018, 10, 152.	4.5	8
35	Effects of Phytochemical P-Glycoprotein Modulators on the Pharmacokinetics and Tissue Distribution of Doxorubicin in Mice. <i>Molecules</i> , 2018, 23, 349.	3.8	21
36	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. <i>Journal of Controlled Release</i> , 2018, 286, 10-19.	9.9	41

#	ARTICLE	IF	CITATIONS
37	Beta-carotene-bound albumin nanoparticles modified with chlorin e6 for breast tumor ablation based on photodynamic therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 171, 123-133.	5.0	37
38	Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel. <i>International Journal of Pharmaceutics</i> , 2017, 519, 11-21.	5.2	37
39	Silver nanoparticle-embedded graphene oxide-methotrexate for targeted cancer treatment. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 153, 95-103.	5.0	68
40	Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy. <i>International Journal of Pharmaceutics</i> , 2017, 527, 61-71.	5.2	47
41	Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 32-44.	4.0	4
42	Polymyxin-resistant, carbapenem-resistant <i>Acinetobacter baumannii</i> is eradicated by a triple combination of agents that lack individual activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1415-1420.	3.0	44
43	Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 885-896.	3.3	57
44	Aminoglycoside Concentrations Required for Synergy with Carbapenems against <i>Pseudomonas aeruginosa</i> Determined via Mechanistic Studies and Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	31
45	Development of a Physiologically Relevant Population Pharmacokinetic <i>in Vitro</i> $\leftrightarrow$ <i>in Vivo</i> Correlation Approach for Designing Extended-Release Oral Dosage Formulation. <i>Molecular Pharmaceutics</i> , 2017, 14, 53-65.	4.6	24
46	Effect of Sipjeondaebotang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. <i>Molecules</i> , 2017, 22, 1488.	3.8	2
47	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. <i>Molecules</i> , 2017, 22, 1515.	3.8	4
48	Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. <i>BMC Pharmacology &amp; Toxicology</i> , 2016, 17, 35.	2.4	2
49	Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. <i>Asian Journal of Pharmaceutical Sciences</i> , 2016, 11, 708-714.	9.1	64
50	An albumin nanocomplex-based endosomal pH-activatable on/off probe system. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 144, 327-334.	5.0	2
51	Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. <i>Journal of Controlled Release</i> , 2016, 225, 301-313.	9.9	147
52	Estimation of nitric oxide synthase activity via liquid chromatography/tandem mass spectrometric assay determination of $^{15}\text{N}_3$ -citrulline in biological samples. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 447-455.	1.5	2
53	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy. <i>International Journal of Nanomedicine</i> , 2015, 10, 739.	6.7	9
54	Simultaneous determination of phenoxyethanol and its major metabolite, phenoxyacetic acid, in rat biological matrices by LC-MS/MS with polarity switching: Application to ADME studies. <i>Talanta</i> , 2015, 144, 29-38.	5.5	16

#	ARTICLE	IF	CITATIONS
55	Synthesis and Caco-2 cell permeability of N-substituted anthranilamide esters as ADP inhibitor in platelets. Archives of Pharmacal Research, 2015, 38, 1147-1156.	6.3	4
56	LC-APCI-MS/MS Quantification and Topical Bioavailability of Chloroacetamide in Rats. Journal of Chromatographic Science, 2015, 53, 1100-1106.	1.4	2
57	Sensitive liquid chromatography-tandem mass spectrometry method for the simultaneous determination of benzyl butyl phthalate and its metabolites, monobenzyl phthalate and monobutyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study. Analytical and Bioanalytical Chemistry, 2015, 407, 7391-7400.	3.7	8
58	Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. AAPS Journal, 2015, 17, 1210-1223.	4.4	20
59	Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. Pharmaceutical Research, 2015, 32, 2912-2927.	3.5	41
60	Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327.	3.2	76
61	A sensitive LC-ESI-MS/MS method for the quantification of avobenzone in rat plasma and skin layers: Application to a topical administration study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1003, 41-46.	2.3	6
62	In situ facile-forming PEG cross-linked albumin hydrogels loaded with an apoptotic TRAIL protein. Journal of Controlled Release, 2015, 214, 30-39.	9.9	50
63	Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer. International Journal of Pharmaceutics, 2015, 494, 506-515.	5.2	45
64	Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane. International Journal of Pharmaceutics, 2015, 495, 93-105.	5.2	4
65	Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth. Journal of Materials Chemistry B, 2015, 3, 408-416.	5.8	37
66	Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization. Pharmaceutical Research, 2015, 32, 1947-1956.	3.5	36
67	In vivo absorption and disposition of $\beta$ -cedrene, a sesquiterpene constituent of cedarwood oil, in female and male rats. Drug Metabolism and Pharmacokinetics, 2015, 30, 168-173.	2.2	14
68	Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. Journal of Controlled Release, 2015, 197, 199-207.	9.9	128
69	Determination of acrylamide and glycidamide in various biological matrices by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Talanta, 2015, 131, 46-54.	5.5	35
70	Absolute bioavailability and metabolism of aceclofenac in rats. Archives of Pharmacal Research, 2015, 38, 68-72.	6.3	13
71	Preparation and evaluation of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-loaded poly(lactic acid) nanoparticles for the treatment of lung cancer. Journal of Pharmaceutical Sciences, 2015, 104, 1075-1085.	6.3	5
72	Size-dependent clearance of gold nanoparticles from lungs of Sprague-Dawley rats after short-term inhalation exposure. Archives of Toxicology, 2015, 89, 1083-1094.	4.2	69

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic Alteration of Baclofen by Multiple Oral Administration of Herbal Medicines in Rats. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-9.	1.2	7
74	Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. Xenobiotica, 2014, 44, 913-925.	1.1	20
75	Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells. Pharmaceutical Research, 2014, 31, 1978-1988.	3.5	70
76	Quantitative Determination of Absorption and First-Pass Metabolism of Apicidin, a Potent Histone Deacetylase Inhibitor. Drug Metabolism and Disposition, 2014, 42, 974-982.	3.3	9
77	Human Serum Albumin-TRAIL Conjugate for the Treatment of Rheumatoid Arthritis. Bioconjugate Chemistry, 2014, 25, 2212-2221.	3.6	41
78	HPLC-MS/MS METHOD FOR THE PHARMACOKINETICS OF HOMOSALATE AFTER TOPICAL ADMINISTRATION IN RATS. Journal of Liquid Chromatography and Related Technologies, 2014, 37, 2465-2477.	1.0	2
79	Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomaterialia, 2014, 10, 5116-5127.	8.3	189
80	Rh-catalyzed oxidative C2-alkenylation of indoles with alkynes: unexpected cleavage of directing group. Tetrahedron Letters, 2014, 55, 3104-3107.	1.4	32
81	Simultaneous determination of 7-O-succinyl macrolactin A and its metabolite macrolactin A in rat plasma using liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 85-89.	2.8	11
82	Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomaterialia, 2014, 10, 142-150.	8.3	40
83	Quantitative Analysis of Ursolic Acid and Euscaphic Acid in Chaenomelis Fructus by HPLC-Evaporative Light Scattering Detection. Bulletin of the Korean Chemical Society, 2014, 35, 2210-2212.	1.9	3
84	Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley rats. Nanotoxicology, 2013, 7, 169-180.	3.0	90
85	Liquid chromatography-tandem mass spectrometry determination of baclofen in various biological samples and application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 938, 43-50.	2.3	15
86	Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials, 2013, 34, 6444-6453.	11.4	115
87	Compounds from the heartwood of Caesalpinia sappan and their anti-inflammatory activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7436-7439.	2.2	56
88	Pharmacokinetics and tissue distribution of psammaplin A, a novel anticancer agent, in mice. Archives of Pharmacal Research, 2012, 35, 1849-1854.	6.3	15
89	Determination and pharmacokinetics of [6]-gingerol in mouse plasma by liquid chromatography-tandem mass spectrometry. Biomedical Chromatography, 2012, 26, 660-665.	1.7	7
90	Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials, 2012, 33, 5574-5583.	11.4	153

#	ARTICLE	IF	CITATIONS
91	Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. <i>Journal of Controlled Release</i> , 2012, 161, 728-734.	9.9	62
92	Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT. <i>AAPS Journal</i> , 2011, 13, 201-211.	4.4	111
93	Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 465-475.	2.3	7
94	Role of metabolism by intestinal bacteria in arbutin-induced toxicity in vitro. <i>Archives of Pharmacal Research</i> , 2011, 34, 687-693.	6.3	20
95	Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry. <i>Archives of Pharmacal Research</i> , 2011, 34, 2073-2078.	6.3	8
96	Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2011, 25, 1208-1214.	1.7	18
97	Population Pharmacokinetics of a Novel Histone Deacetylase Inhibitor, Cyclo{(2S)-2-Amino-8-[(Aminocarbonyl)Hydrazono]Decanoyl-1- <i>L</i> -Tryptophyl- <i>L</i> -Isoleucyl-(2R)-2-Piperidinecarbonyl} (SD-2007), and Its Metabolic Conversion to Apicidin after Intravenous Injection and Oral Administration in Rats. <i>Chemotherapy</i> , 2011, 57, 259-267.	1.6	1
98	Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2010, 73, 1586-1598.	2.3	20
99	Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 580-591.	2.5	38
100	Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and <i>in vitro</i> hepatic metabolic clearance. <i>Biomedical Chromatography</i> , 2009, 23, 764-769.	1.7	11
101	Determination of zearalenone by liquid chromatography/tandem mass spectrometry and application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2009, 23, 1014-1021.	1.7	27
102	Interspecies scaling of oleanolic acid in mice, rats, rabbits and dogs and prediction of human pharmacokinetics. <i>Archives of Pharmacal Research</i> , 2009, 32, 251-257.	6.3	12
103	Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 87-94.	2.3	21
104	Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 837-841.	2.3	41
105	Development and validation of a reversed-phase fluorescence HPLC method for determination of bucillamine in human plasma using pre-column derivatization with monobromobimane. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2130-2134.	2.3	2
106	Analysis of enantiomers of sibutramine and its metabolites in rat plasma by liquid chromatography-mass spectrometry using a chiral stationary-phase column. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 50, 267-270.	2.8	18
107	Development of a Sensitive LC Assay with Fluorescence Detection for the Determination of Zearalenone in Rat Serum. <i>Chromatographia</i> , 2009, 69, 295-299.	1.3	9
108	Physiologically Based Pharmacokinetics of Zearalenone. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2009, 72, 1395-1405.	2.3	30



#	ARTICLE	IF	CITATIONS
109	Disposition, Oral Bioavailability, and Tissue Distribution of Zearalenone in Rats at Various Dose Levels. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2009, 72, 1406-1411.	2.3	38
110	Biochanin A Inhibits Breast Cancer Tumor Growth in A Murine Xenograft Model. <i>Pharmaceutical Research</i> , 2008, 25, 2158-63.	3.5	62
111	Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats. <i>Archives of Pharmacal Research</i> , 2008, 31, 117-124.	6.3	10
112	LC-MS-MS Determination of Cyclo{(2S)-2-amino-8-[(aminocarbonyl)hydrazono]decanoyl-1-l-tryptophyl-l-isooleucyl-(2R)-2-piperidinecarbonyl} a Novel Histone Deacetylase Inhibitor in Rat Serum. <i>Chromatographia</i> , 2008, 67, 231-235.	1.3	2
113	Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. <i>Regulatory Peptides</i> , 2007, 140, 74-80.	1.9	5
114	Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. <i>Biomedical Chromatography</i> , 2007, 21, 883-889.	1.7	40
115	Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in Mice. <i>Archives of Pharmacal Research</i> , 2007, 30, 1162-1167.	6.3	0
116	Development of LC/MS/MS assay for the determination of 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl]-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 45, 176-184.	2.8	13
117	Pharmacokinetics of a novel histone deacetylase inhibitor, apicidin, in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 69-75.	1.9	9
118	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 977-984.	1.0	40
119	Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 408-414.	1.5	13
120	In Vitro Investigation of the Hepatic Intrinsic Clearance of Apicidin, a Histone Deacetylase Inhibitor, in Mouse, Rat, and Human, with Correction by Nonspecific Protein Binding. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2005, 68, 2207-2218.	2.3	1
121	Altered Oral Absorption of Alcohol by Combined Aqueous Extracts of Four Herbal Plants in Rats. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2005, 68, 2219-2226.	2.3	5
122	Dose-linear pharmacokinetics, tissue distribution, and excretion of a recombinant fusion protein 125I-GST-TatdMt possessing potent anti-obesity activity. <i>Regulatory Peptides</i> , 2005, 129, 25-30.	1.9	5
123	PHYSIOLOGICALLY BASED PHARMACOKINETICS OF BISPHENOL A. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2004, 67, 1971-1985.	2.3	55
124	Oral Absorption and Pharmacokinetics of Rebamipide and Rebamipide Lysinate in Rats. <i>Drug Development and Industrial Pharmacy</i> , 2004, 30, 869-876.	2.0	23
125	Nasal Absorption and Pharmacokinetic Disposition of Salmon Calcitonin Modified with Low Molecular Weight Polyethylene Glycol. <i>Chemical and Pharmaceutical Bulletin</i> , 2004, 52, 957-960.	1.3	15
126	MATERNAL-FETAL DISPOSITION OF BISPHENOL A IN PREGNANT SPRAGUE-DAWLEY RATS. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2002, 65, 395-406.	2.3	38



#	ARTICLE	IF	CITATIONS
127	Pharmacokinetic scaling of bisphenol A by species-invariant time methods. <i>Xenobiotica</i> , 2002, 32, 925-934.	1.1	22
128	Interspecies comparison of the oral absorption of itraconazole in laboratory animals. <i>Archives of Pharmacal Research</i> , 2002, 25, 387-391.	6.3	20
129	Pharmacokinetic Disposition of Polyethylene Glycol-Modified Salmon Calcitonins in Rats.. <i>Chemical and Pharmaceutical Bulletin</i> , 2000, 48, 1921-1924.	1.3	26
130	Absorption, First-Pass Metabolism, and Disposition of Itraconazole in Rats.. <i>Chemical and Pharmaceutical Bulletin</i> , 2000, 48, 798-801.	1.3	28